Literature DB >> 29296905

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants.

Jordan K Schaefer1, Suman L Sood1, Brian Haymart2, Xiaokui Gu2, Xiaowen Kong2, Eva Kline-Rogers2, Steven Almany3, Jay Kozlowski4, Gregory D Krol5, Scott Kaatz5, James B Froehlich2, Geoffrey D Barnes2.   

Abstract

Clinical factors and patient preferences are important for selecting oral anticoagulants for venous thromboembolism (VTE) and atrial fibrillation (AF). The relative association of sociodemographic factors with anticoagulant use is unknown. We evaluated a prospective cohort to compare sociodemographic variables in patients who continued on warfarin for AF or VTE to those who transitioned to 1 of the direct oral anticoagulants (DOACs). Adult patients, newly started on warfarin, were enrolled through 6 anticoagulation clinics across Michigan. Of 8468 patients, 53.3% had AF, 45.6% had VTE, and 1.1% had both. Of these, 696 (8.2%) switched from warfarin to a DOAC. There were no significant differences between switchers and nonswitchers for percentage of time with a therapeutic international normalized ratio on warfarin, urban-rural residence status, or health insurance. Switchers were more often white (83.3% vs 77.7%; P < .001), partnered (67.3% vs 59.2%; P < .001), or resided in a zip code with a higher median household income (P < .001). The results show that sociodemographic factors, such as race, partnered status, and income are associated with a patient's likelihood of switching to a DOAC vs remaining on warfarin therapy. Although clinical factors predominate, the reason for, and impact of, these observed variations in care requires further investigation.

Entities:  

Year:  2017        PMID: 29296905      PMCID: PMC5728645          DOI: 10.1182/bloodadvances.2017012377

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  13 in total

Review 1.  The social determinants of health: it's time to consider the causes of the causes.

Authors:  Paula Braveman; Laura Gottlieb
Journal:  Public Health Rep       Date:  2014 Jan-Feb       Impact factor: 2.792

2.  Marriage Meets the Joneses: Relative Income, Identity, and Marital Status.

Authors:  Tara Watson; Sara McLanahan
Journal:  J Hum Resour       Date:  2011-06-20

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 4.  Traveling towards disease: transportation barriers to health care access.

Authors:  Samina T Syed; Ben S Gerber; Lisa K Sharp
Journal:  J Community Health       Date:  2013-10

5.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

Review 6.  Engaging with quality improvement in anticoagulation management.

Authors:  Geoffrey D Barnes; Eva Kline-Rogers
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 7.  Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.

Authors:  Elaine M Hylek
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

8.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

9.  The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation.

Authors:  Michelle Sholzberg; Tara Gomes; David N Juurlink; Zhan Yao; Muhammad M Mamdani; Andreas Laupacis
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

Review 10.  How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.

Authors:  Jordan K Schaefer; Robert D McBane; Waldemar E Wysokinski
Journal:  Ann Hematol       Date:  2015-12-11       Impact factor: 3.673

View more
  1 in total

1.  Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data.

Authors:  Daniel Hill-McManus; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2022-01-25       Impact factor: 3.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.